Table 1.
Association between lnc-CRAT40 expression levels and clinicopathological features in colorectal cancer patients (n = 103).
| N (%) | CRAT40 expression | p-value | ||
|---|---|---|---|---|
| high | low | |||
| Gender | 0.500 | |||
| Female | 70 (68.0%) | 41 (58.6%) | 29 (41.4%) | |
| Male | 33 (32.0%) | 17 (51.5%) | 16 (48.5%) | |
| Age (years) | 0.104 | |||
| <60 | 49 (47.6%) | 23 (46.9%) | 26 (53.1%) | |
| ≥60 | 54 (52.4%) | 35 (64.8%) | 19 (35.2%) | |
| Location | 0.105 | |||
| Colon | 39 (37.9%) | 18 (46.2%) | 21 (53.8%) | |
| Rectum | 64 (62.1%) | 40 (62.5%) | 24 (37.5%) | |
| T stage | 0.877 | |||
| T1-T2 | 19 (18.4%) | 11 (57.9%) | 8 (42.1%) | |
| T3-T4 | 84 (81.6%) | 47 (56.0%) | 37 (44.0%) | |
| N stage | 0.604 | |||
| N0-N1 | 92 (89.3%) | 51 (55.4%) | 41 (44.6%) | |
| N2-N3 | 11 (10.7%) | 7 (63.6%) | 4 (36.4%) | |
| M stage | 0.801 | |||
| M0 | 88 (85.4%) | 50 (56.8%) | 38 (43.2%) | |
| M1 | 15 (14.6%) | 8 (53.3%) | 7 (46.7%) | |
| Stage | 0.287 | |||
| I/II | 58 (56.3%) | 30 (51.7%) | 28 (48.3%) | |
| III/IV | 45 (43.7%) | 28 (62.2%) | 17 (37.8%) | |
| Lymphatic | 0.031 | |||
| No | 61 (59.2%) | 29 (47.5%) | 32 (52.5%) | |
| Yes | 42 (40.8%) | 29 (69.0%) | 13 (31.0%) | |
| Distant metastasis | 0.165 | |||
| No | 91 (88.3%) | 49 (53.8%) | 42 (46.2%) | |
| Yes | 12 (11.7%) | 9 (75.0%) | 3 (25.0%) | |